UiPath plunges after Q4 results, but Needham upgrades to Buy on new ARR

UiPath (PATH) stock slides after Q4 FY26 results as Needham upgrades to Buy on ARR and free cash flow growth; AI ARR hits $200M.
Hosted on MSN

How UiPath (PATH) is using agentic AI to tackle healthcare payment bottlenecks

UiPath, Inc. (NYSE:PATH) is one of the cheap AI stocks to buy in 2026. On February 23, 2026, UiPath announced a suite of agentic AI solutions for healthcare providers and payers, targeting ...
Yahoo Finance

UiPath Launches Agentic AI Solutions to Break Administrative & Financial Bottlenecks for Clinicians and Healthcare Admins

NEW YORK, February 23, 2026--(BUSINESS WIRE)--UiPath (NYSE: PATH), a global leader in agentic automation, today announced new agentic AI solutions for the healthcare industry for providers and payers ...
Nasdaq

Battle Royale: Nebius vs. UiPath. Only One Can Make You Rich.

In its latest earnings report, Nebius reported a 547% increase in quarterly revenue compared to the year prior. UiPath achieved its first GAAP profitable quarter in the company's third-quarter fiscal ...